2026-01-06 - Analysis Report
Okay, let's break down this Honeywell (HON) analysis.

**0. Report Format**

The report will present data points first, followed by a simple analysis of each point. A comprehensive summary will conclude the report.

**1. Return Rate vs. S&P 500 (VOO)**

*   **HON Overview:** Honeywell International Inc. is a diversified technology and manufacturing company.

*   **Cumulative Return (HON):** 10.67%
*   **Cumulative Return (VOO):** 91.00%
*   **Divergence:** -80.3 (Relative Divergence: 3.6)

**Analysis:**

*   HON has significantly underperformed the S&P 500 (VOO) over the analyzed period.
*   The divergence of -80.3 indicates a substantial gap in cumulative returns.
*   The relative divergence of 3.6 suggests that the current divergence is near the lowest it has been within the observed range (a low percentile position).

**Alpha, Beta Analysis:**

| Year      | CAGR   | MDD    | Alpha    | Beta   | Cap(B) |
| ----------- | ------ | ------ | -------- | ------ | ------ |
| 2016-2018 | 2.0%   | 19.7%  | -2.0%    | 0.9    | 86.1   |
| 2017-2019 | 23.0%  | 19.7%  | 5.0%     | 1.0    | 115.4  |
| 2018-2020 | 4.0%   | 19.7%  | -17.0%   | 1.1    | 138.7  |
| 2019-2021 | 17.0%  | 18.8%  | -27.0%   | 1.1    | 135.9  |
| 2020-2022 | 8.0%   | 17.6%  | 10.0%    | 1.0    | 139.7  |
| 2021-2023 | -8.0%  | 17.6%  | -9.0%    | 0.8    | 136.7  |
| 2022-2024 | -1.0%  | 17.0%  | -20.0%   | 0.8    | 147.3  |
| 2023-2025 | -16.0% | 19.7%  | -78.0%   | 0.8    | 135.0  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows inconsistent performance, with some periods showing positive growth and others negative. The most recent period (2023-2025) is particularly weak.
*   **MDD:** The Maximum Drawdown is consistently around 17-20%, indicating a moderate level of risk.
*   **Alpha:**  Alpha is frequently negative, indicating HON has often underperformed relative to its risk (Beta). The 2020-2022 period is a notable exception.
*   **Beta:** Beta hovers around 0.8-1.1. A beta close to 1 suggests the stock's price tends to move similarly to the market.
*   **Cap(B):**  Market Cap is in Billions, showing HON is a large-cap company.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 195.88
*   **Last Market Data:** Price: 201.09, Previous Close: 195.88, Change: 2.66
*   **5-day SMA:** 196.36
*   **20-day SMA:** 195.41
*   **60-day SMA:** 195.45

**Analysis:**

*   The stock price closed at 195.88, but the last market data price is 201.09, with a positive change of 2.66, indicating an upward movement after the close.
*   The 5-day SMA is slightly above the 20-day and 60-day SMAs, suggesting a possible short-term upward trend.
*   All SMAs are relatively close, indicating a period of price consolidation.

**3. RSI, PPO, and Divergence Indicators**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 55.70
*   **PPO:** -0.01
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent Relative Divergence Change (20 days):** 2.2 (+) (Short-term Increase)
*   **Expected Return (%):** -794.4

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI is at 55.70, indicating a neutral position (neither overbought nor oversold).
*   The PPO is slightly negative, suggesting a potential slight downward trend, but is close to zero.
*   The Hybrid Signal indicates a buy signal, using most of the cash, given the MRI.
*   The positive change in recent relative divergence indicates a short-term upward movement.
*   The *very* negative Expected Return is extremely concerning and warrants further investigation. It might be an error in calculation or indicate a very pessimistic outlook.

**4. Recent News & Significant Events**

*   **[2026-01-05] Fund Update:** Confluence Investment Management opens a $100.9M position in HON.
*   **[2025-12-31] Government Contract:** Honeywell receives a $58.8 million Army contract modification.
*   **[2026-01-05] Valuation:** An article discusses whether HON is offering value after mixed share price performance.
*   **[2025-12-16] Board Changes:** Indra Nooyi joins Honeywell's board.
*   **[2026-01-05] Institutional Ownership:** KG&L Capital Management acquires shares of Honeywell.
*   **[2025-12-22] Profit Outlook:** Honeywell lowers its profit outlook due to a $470 million Flexjet problem.

**Analysis:**

*   The news is mixed. Positive news includes a new large investment by Confluence, a government contract modification, and new institutional ownership.
*   The appointment of Indra Nooyi to the board could be seen as a positive signal.
*   However, the lowered profit outlook due to the Flexjet problem is a significant negative.  This explains some of the negative sentiment and potential underperformance.
*   The article questioning HON's valuation is also a point of concern.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.07)
*   **Opinions:** 24 analysts
*   **Target Price:** Average: $235.57, High: $271.00, Low: $195.00
*   **Recent Rating Changes:** No changes listed

**Analysis:**

*   The analyst consensus is "Buy," suggesting a positive outlook.
*   The average target price of $235.57 is significantly higher than the current price, implying potential upside. However, there is a wide range between the high and low target prices, indicating uncertainty among analysts.
*   The lack of recent rating changes makes it difficult to understand the context and reason for the buy. The "buy" needs further investigation.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
| ---------- | ---- | ---------- |
| 2025-10-23 | 2.87 | 10.41 B$   |
| 2025-07-24 | 2.46 | 10.35 B$   |
| 2025-04-29 | 2.24 | 9.82 B$    |
| 2024-10-24 | 2.17 | 9.73 B$    |
| 2025-10-23 | 2.17 | 9.73 B$    |

**Analysis:**

*   Earnings per share (EPS) has generally been increasing over the past year.
*   Revenue has also shown a general upward trend.
*   2025-10-23 has the same value as 2024-10-24, might be a duplicated entry or incorrect entry.

**6. Financial Information (Revenue & Profitability, Capital & Profitability)**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | --------------- |
| 2025-09-30 | $10.41B  | 34.08%         |
| 2025-06-30 | $10.35B  | 38.86%         |
| 2025-03-31 | $9.82B   | 38.54%         |
| 2024-12-31 | $10.09B  | 36.38%         |
| 2024-09-30 | $9.73B   | 38.54%         |

**Analysis:**

*   Revenue has been relatively stable around $10 billion per quarter, with slight fluctuations.
*   Profit margins have also been relatively consistent, fluctuating around 36-39%.

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
| ---------- | --------- | -------- |
| 2025-09-30 | $16.78B  | 10.87%   |
| 2025-06-30 | $16.09B  | 9.75%    |
| 2025-03-31 | $17.46B  | 8.30%    |
| 2024-12-31 | $18.62B  | 6.90%    |
| 2024-09-30 | $17.41B  | 8.12%    |

**Analysis:**

*   Equity has decreased over the past year.
*   Return on Equity (ROE) has increased, but it's fluctuating and needs to be evaluated relative to industry peers.

**7. Comprehensive Analysis**

Honeywell (HON) presents a mixed picture. The stock has significantly underperformed the S&P 500, with a large divergence in cumulative returns. The negative Alpha values reinforces this underperformance. Recent news highlights a lowered profit outlook due to issues with Flexjet, which likely contributes to investor concern. However, there are positive signs, including a recent investment by Confluence, a government contract, and analyst consensus rating of "Buy" with a target price.

The technical indicators present a neutral stance. The RSI is neither overbought nor oversold, and the PPO is only slightly negative. The MRI suggests a moderate investment recommendation. The sharp rebound shows how volatile HON can be as the market is still not done with the fundamental problems the company faces.

While revenue and profit margins have been relatively stable, equity has been declining, and ROE has been volatile.

**Overall Recommendation:**

Given the mixed signals and the underperformance relative to the S&P 500, a cautious approach is warranted. Further investigation into the Flexjet problem and the reason for the extremely negative expected return is crucial. The analyst's buy recommendations and target price need to be validated against the negative news. A hold or underweight position might be appropriate until more clarity emerges. Be careful about "catching a falling knife".



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.